| Autor: |
Jiun‐Lu Lin, Sung‐Chen Liu, Tze‐Fan Liu, Shih‐Ming Chuang, Chun‐Ta Huang, Ying‐Ju Chen, Chun‐Chuan Lee, Ming‐Nan Chien, Charles Jia‐Yin Hou, Hung‐I. Yeh, Chern‐En Chiang, Chung‐Lieh Hung |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 9 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2047-9980 |
| DOI: |
10.1161/JAHA.123.033832 |
| Popis: |
Background Dapagliflozin, a sodium–glucose cotransporter 2 inhibitor, is an epochal oral antidiabetic drug that improves cardiorenal outcomes. However, the effect of early dapagliflozin intervention on left ventricular (LV) remodeling in patients with type 2 diabetes free from cardiovascular disease remains unclear. Methods and Results The ELUCIDATE trial was a prospective, open‐label, randomized, active‐controlled study that enrolled 76 patients with asymptomatic type 2 diabetes with LV ejection fraction ≥50%, randomized to the dapagliflozin 10 mg/day add‐on or standard‐of‐care group. Speckle‐tracking echocardiography–based measurements of the cardiac global longitudinal strain were performed at baseline and 24 weeks after treatment initiation. Patients who received dapagliflozin had a greater reduction in LV dimension (1.68 mm [95% CI, 0.53–2.84]; P=0.005), LV end‐systolic volume (5.51 mL [95% CI, 0.86–10.17]; P=0.021), and LV mass index (4.25 g/m2.7 [95% CI, 2.42–6.09]; P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text